Noncutaneous malignant melanoma: A prognostic model from a retrospective multicenter study

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Kim, Hyo Song ^a,e   Kim, Eun Kyoung ^b   Jun, Hyun Jung ^a   Oh, Sung Yong ^c   Park, Keon Woo ^d   Lim, Do Hyoung ^d   Lee, Soon Il ^d   Kim, Jung Han ^a   Kim, Kyoung Mee ^a   Lee, Dae Ho ^b   Lee, Jeeyun ^a  

^a Samsung Medical Center   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Dong A University College of Medicine   (South Korea)

^d Dankook University   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; AGING; ANORECTAL MELANOMA; ARTICLE; CANCER LOCALIZATION; CANCER SURGERY; CANCER SURVIVAL; CHOROID MELANOMA; CONJUNCTIVAL MELANOMA; FEMALE; GENITOURINARY MELANOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXILLA SINUS MELANOMA; MELANOMA; NOSE MELANOMA; ORAL MELANOMA; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SOLID TUMOR; SURVIVAL RATE; SURVIVAL TIME; UPPER GASTROINTESTINAL MELANOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CANCER STAGING; CARCINOMA; CLINICAL TRIAL; EYE TUMOR; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MUCOSA; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SOUTH KOREA; TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHEMOTHERAPY, ADJUVANT; EYE NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MUCOUS MEMBRANE; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951615425     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-167     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010, 18287387.
2. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998, 83(8):1664-1678. 10.1002/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G, 9781962.
3. Berthelsen A, Andersen AP, Jensen TS, Hansen HS. Melanomas of the mucosa in the oral cavity and the upper respiratory passages. Cancer 1984, 54(5):907-912. 10.1002/1097-0142(19840901)54:5<907::AID-CNCR2820540526>3.0.CO;2-Z, 6744219.
4. Guzzo M, Grandi C, Licitra L, Podrecca S, Cascinelli N, Molinari R. Mucosal malignant melanoma of head and neck: forty-eight cases treated at Istituto Nazionale Tumori of Milan. Eur J Surg Oncol 1993, 19(4):316-319.
5. Rapini RP, Golitz LE, Greer RO, Krekorian EA, Poulson T. Primary malignant melanoma of the oral cavity. A review of 177 cases. Cancer 1985, 55(7):1543-1551. 10.1002/1097-0142(19850401)55:7<1543::AID-CNCR2820550722>3.0.CO;2-F, 3978548.
6. Neugut AI, Kizelnik-Freilich S, Ackerman C. Black-white differences in risk for cutaneous, ocular, and visceral melanomas. Am J Public Health 1994, 84(11):1828-1829. 10.2105/AJPH.84.11.1828, 1615205, 7977927.
7. Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of california cancer registry data, 1988-93. Cancer Causes Control 1997, 8(2):246-252. 10.1023/A:1018432632528, 9134249.
8. Chaudhry AP, Hampel A, Gorlin RJ. Primary malignant melanoma of the oral cavity: a review of 105 cases. Cancer 1958, 11(5):923-928. 10.1002/1097-0142(195809/10)11:5<923::AID-CNCR2820110507>3.0.CO;2-1, 13585343.
9. Kato T, Takematsu H, Tomita Y, Takahashi M, Abe R. Malignant melanoma of mucous membranes. A clinicopathologic study of 13 cases in Japanese patients. Arch Dermatol 1987, 123(2):216-220. 10.1001/archderm.123.2.216, 3813595.
10. Omura K, Takemiya S, Shimada F, Shimada A, Ono I, Uchida M, Tanigawa Y, Matsuura S, Takeoda K. [Malignant mucosal melanomas of the head and neck--collective review from six cancer hospitals]. Gan No Rinsho 1986, 32(12):1511-1518.
11. Hu DN, Yu G, McCormick SA, Finger PT. Population-based incidence of conjunctival melanoma in various races and ethnic groups and comparison with other melanomas. Am J Ophthalmol 2008, 145(3):418-423. 10.1016/j.ajo.2007.10.022, 18191091.
12. Hu DN, Yu GP, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol 2005, 140(4):612-617.
13. Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F, Azar S, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008, 14(21):6821-6828. 10.1158/1078-0432.CCR-08-0575, 18980976.
14. Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer 1997, 80(8):1373-1386. 10.1002/(SICI)1097-0142(19971015)80:8<1373::AID-CNCR3>3.0.CO;2-G, 9338460.
15. DeMatos P, Tyler DS, Seigler HF. Malignant melanoma of the mucous membranes: a review of 119 cases. Ann Surg Oncol 1998, 5(8):733-742. 10.1007/BF02303485, 9869521.
16. Mendenhall WM, Amdur RJ, Hinerman RW, Werning JW, Villaret DB, Mendenhall NP. Head and neck mucosal melanoma. Am J Clin Oncol 2005, 28(6):626-630. 10.1097/01.coc.0000170805.14058.d3, 16317276.
17. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19(16):3635-3648.
18. Iversen K, Robins RE. Mucosal malignant melanomas. Am J Surg 1980, 139(5):660-664. 10.1016/0002-9610(80)90358-X, 7468915.
19. Wong JH, Cagle LA, Storm FK, Morton DL. Natural history of surgically treated mucosal melanoma. Am J Surg 1987, 154(1):54-57. 10.1016/0002-9610(87)90289-3, 2440332.
20. Macak J. Melanoma of the stomach: reality or fiction?. Pathologica 1998, 90(4):388-390.
21. Jelincic Z, Jakic-Razumovic J, Petrovic I, Cavcic AM, Unusic J, Trotic R. Primary malignant melanoma of the stomach. Tumori 2005, 91(2):201-203.
22. Dabrowski A, Zinkiewicz K, Szumilo J, Zgodzinski W, Cwik G, Skoczylas T, Wallner G. Unusual clinical course of metachronous melanomas of the upper digestive system. World J Gastroenterol 2005, 11(14):2197-2199.
23. Wada H, Nemoto K, Ogawa Y, Hareyama M, Yoshida H, Takamura A, Ohmori K, Hamamoto Y, Sugita T, Saitoh M, et al. A multi-institutional retrospective analysis of external radiotherapy for mucosal melanoma of the head and neck in Northern Japan. Int J Radiat Oncol Biol Phys 2004, 59(2):495-500.
24. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14(1):7-17.
25. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004, 10(5):1670-1677. 10.1158/1078-0432.CCR-1103-3, 15014018.
26. Jacquillat C, Khayat D, Banzet P, Weil M, Avril MF, Fumoleau P, Namer M, Bonneterre J, Kerbrat P, Bonerandi JJ, et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 1990, 25(4):263-266. 10.1007/BF00684883, 2403853.
27. Clark J, Moon J, Hutchins LF, Sosman JA, Kast WM, Silva DD, Liu PY, Thompson JA, Sondak VK. Phase II trial of combination thalidomide (thal) plus temozolomide (TMZ [TT]), in patients with metastatic malignant melanoma (MMM): Southwest Oncology Group S0508. J Clin Oncol 2008, 26 (May 20 suppl; abstr 9007).
28. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A, Simon R, et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004, 22(22):4514-4522. 10.1200/JCO.2004.10.125, 15542802.
29. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006, 24(26):4340-4346. 10.1200/JCO.2006.06.2984, 16908931.
30. Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007, 121(2):257-264. 10.1002/ijc.22681, 17372901.
31. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, Jagannathan J, Abbeele AD, Velazquez EF, Demetri GD, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008, 26(12):2046-2051. 10.1200/JCO.2007.14.0707, 18421059.
32. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008, 21(4):492-493. 10.1111/j.1755-148X.2008.00475.x, 18510589.